Citrin Cooperman today announced it acquired Browne Consulting Group, expanding its presence in Boston and strengthening its expertise in the life sciences and biotech sectors.
Browne, which is based in Boston, adds roughly 60 employees to the Top 25 Firm, which is based in New York City. Terms of the deal were not disclosed.
Citrin Cooperman is backed by private equity. In April 2022, New Mountain Capital acquired a majority interest in Citrin, fueling a
"Our organizations share a deep commitment to client service, a collaborative culture, and a passion for delivering strategic, industry-specific insights," Alan Badey, CEO of Citrin Cooperman Advisors, said in a statement. "Browne's deep expertise in life sciences and biotech consulting will accelerate our growth in this high-impact sector. Together, we'll deliver even greater value to our clients as they navigate the complexities of innovation, regulation, and growth in the life sciences ecosystem."
Citrin Cooperman ranked No. 17 on Accounting Today's 2025 Top 100 Firms list, reporting $870 million in revenue, with over 3,600 total employees across at least 27 offices.
"We couldn't be more excited to join forces with Citrin Cooperman," Warren Browne, founder and CEO of Browne Consulting, said in a statement. "Our cultural synergies and shared commitment to integrity, innovation and client success have been evident since our early discussions. Citrin Cooperman's reach and resources, paired with our deep specialized experience in life sciences and biotech, creates a powerful platform to help our clients solve their most complex challenges."
Browne was founded in 2016 and provides accounting and finance services to venture capital-backed life science companies in the Boston area.
Koltin Consulting Group CEO Allan Koltin, who advised both firms on the transaction, said, "I congratulate both organizations on structuring a deal that not only makes strategic sense but also respects and enhances the unique cultural DNA of each firm. Their collective expertise in navigating life sciences opportunities will be a formidable offering for clients seeking trusted partners in a rapidly evolving space."
